Skystar Bio Pharmaceutical Company announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $14,239,605 against $11,335,145 a year ago. Income from operations was $3,367,731 against $4,546,248 a year ago. Income before provision for income taxes was $3,493,149 against $4,447,638 a year ago. Net income was $2,810,760 against $3,750,881 a year ago. Diluted earnings per share were $0.36 against basic and diluted earnings per share of $0.49 a year ago. Overall increase in revenue was primarily due to an increase in its veterinary medications sales.

For the six months, the company reported revenue of $21,072,193 against $16,865,886 a year ago. Income from operations was $4,540,078 against $5,616,533 a year ago. Income before provision for income taxes was $4,898,626 against $5,481,655 a year ago. Net income was $3,786,210 against $4,463,614 a year ago. Basic and diluted earnings per share were $0.49 against $0.59 a year ago. Net cash provided by operating activities was $10,016,900 against net cash used in operating activities of $10,634,524 a year ago.

The company anticipates delivering an 8% to 18% year over year increase in top line revenue for fiscal 2014 as compared to the prior year. The expected revenue range is $46 million to $50 million with gross margin of roughly 50% for fiscal 2014.